KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Gilead Sciences (GILD) Asset Writedowns and Impairment (2016 - 2025)

Gilead Sciences filings provide 5 years of Asset Writedowns and Impairment readings, the most recent being $400.0 million for Q4 2025.

On a quarterly basis, Asset Writedowns and Impairment changed N/A to $400.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $590.0 million, a 85.95% decrease, with the full-year FY2025 number at $590.0 million, down 85.89% from a year prior.
Asset Writedowns and Impairment hit $400.0 million in Q4 2025 for Gilead Sciences, up from $190.0 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $2.7 billion in Q1 2022 to a low of $50.0 million in Q4 2023.
Median Asset Writedowns and Impairment over the past 4 years was $1.1 billion (2024), compared with a mean of $1.3 billion.